TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34150661

Group type: EXPERIMENTAL
Intervention: Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Access to the fertility unit for complete oncofertility counseling
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cryopreservation technique
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Hormone-receptor positive breast cancer
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Concerns about chemotherapy-induced premature ovarian insufficiency and/or infertility
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cryopreservation strategies
Number of subjects: 223
Study: 34150785

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen with different haploidentical donors (HIDs) including fludarabine (30 mg/m2)
Number of subjects: 0
Study: 34150872

Group type: EXPERIMENTAL
Intervention: Weight change intervention, details not available
Number of subjects: 0
Study: 34150923

Group type: EXPERIMENTAL
Intervention: Qvella's FAST HR process for quantifying host gene expression signatures in whole blood
Number of subjects: 128
Study: 34151781

Group type: EXPERIMENTAL
Intervention: Acute triiodothyronine administration
Number of subjects: 0
Study: 34151947

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) using a multi-electrode pentaspline catheter with a biphasic waveform
Number of subjects: 59

Group type: COMPARATOR
Intervention: Thermal Ablation (including 29 radiofrequency ablation, 6 cryoballoon, and 4 visually guided laser balloon)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Thermal Ablation (RFA)
Number of subjects: 59
Study: 34152067

Group type: EXPERIMENTAL
Intervention: Patient-centred PEP programme with 28-day regimen; PEP availability seven days/week, PEP hotline, out-of-facility medication delivery.
Number of subjects: 124
Study: 34152281

Group type: EXPERIMENTAL
Intervention: Usual care plus TB treatment support tools (TB-TSTs)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 34152395

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 320 mg once daily
Number of subjects: 32
Study: 34152570

Group type: EXPERIMENTAL
Intervention: Peer-led groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician-led groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internet-based eBody Project
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 0
Study: 34152585

Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg BID for 14 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 34152703

Group type: EXPERIMENTAL
Intervention: Exercise training (low-to-moderate intensity)
Number of subjects: 615
Study: 34152898

Group type: EXPERIMENTAL
Intervention: Autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) administered at doses of 9 × 10
Number of subjects: 0
Study: 34153013

Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for efavirenz (EFV)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for lopinavir (LPV)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Qualitative point-of-care drug level tests for dolutegravir (DTG)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for efavirenz (EFV)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for lopinavir (LPV)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Simulated treatment cessation for dolutegravir (DTG)
Number of subjects: 83
Study: 34153017

Group type: EXPERIMENTAL
Intervention: Preoperative biomarker panel (including NT-proBNP, hs-CRP, hemoglobin, magnesium)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Clinical risk factors (EuroSCORE II)
Number of subjects: 539
Study: 34153099

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 4755

Group type: COMPARATOR
Intervention: Nonplasma (control)
Number of subjects: 4755

Group type: COMPARATOR
Intervention: Convalescent plasma vs Nonplasma
Number of subjects: 4755
Study: 34153116

Group type: EXPERIMENTAL
Intervention: Adaptation of management protocols during COVID-19 pandemic, specific details not available.
Number of subjects: 0
Study: 34153264

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (two doses given 4-6 weeks apart)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 54
Study: 34154392

Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 0
Study: 34154444

Group type: EXPERIMENTAL
Intervention: Caregiver-reported impact of patients' abnormal involuntary movements
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of caregiver ratings with patient ratings
Number of subjects: 41
Study: 34154504

Group type: EXPERIMENTAL
Intervention: Medtronic Extended Infusion Set (EIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 2- to 3-day infusion sets
Number of subjects: 0
Study: 34154614

Group type: EXPERIMENTAL
Intervention: Envafolimab 150 mg subcutaneously weekly in a 28-day treatment cycle
Number of subjects: 103
Study: 34154665

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (HEI-2015) dietary patterns
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Sex and age diet pattern models
Number of subjects: 393
Study: 34154670

Group type: EXPERIMENTAL
Intervention: Facilitation intensity and facilitator resilience as proposed factors in the facilitation process.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support for facilitator resilience in healthcare delivery systems.
Number of subjects: 0
Study: 34154675

Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 34155079

Group type: EXPERIMENTAL
Intervention: Transition readiness and care experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition process
Number of subjects: 0
Study: 34155084

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a dose range of 30-50 Gy delivered in 1, 3, or 5 daily fractions to all sites of active metastatic disease.
Number of subjects: 205
Study: 34155171

Group type: EXPERIMENTAL
Intervention: Capnodynamic method (COEPBF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (COTPTD)
Number of subjects: 35
Study: 34155211

Group type: EXPERIMENTAL
Intervention: Myo-inositol trispyrophosphate (ITPP)
Number of subjects: 28
Study: 34155277

Group type: EXPERIMENTAL
Intervention: Newly diagnosed DM
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: Known DM
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: No DM
Number of subjects: 1306
Study: 34155622

Group type: COMPARATOR
Intervention: Oral misoprostol (initial dose ≤ 50 µg)
Number of subjects: 20026

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 20026
Study: 34155864

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (BMSCs) and growth factors used for activation of ovarian tissue before re-transplantation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mesenchymal stem cells (BMSCs) and growth factors
Number of subjects: 50
Study: 34155907

Group type: EXPERIMENTAL
Intervention: Virtual visits after blood pressure control was achieved
Number of subjects: 10

Group type: COMPARATOR
Intervention: In-person visits prior to achieving BP control
Number of subjects: 10
Study: 34155911

Group type: EXPERIMENTAL
Intervention: Quantitative MRI assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscle volume measurements
Number of subjects: 0
Study: 34156285

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 0
Study: 34156303

Group type: EXPERIMENTAL
Intervention: High burden of small airway disease (SAD) ≥15.6%
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: High burden of emphysema ≥5%
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Severe exacerbations requiring hospitalization
Number of subjects: 737
Study: 34156440

Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and mycophenolate mofetil
Number of subjects: 38
Study: 34156524

Group type: EXPERIMENTAL
Intervention: BASILICA procedure
Number of subjects: 15

Group type: COMPARATOR
Intervention: TAVI without prior successful bioprosthetic leaflet laceration
Number of subjects: 15
Study: 34156525

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 1685
Study: 34156589

Group type: EXPERIMENTAL
Intervention: Depressed Veterans with PTSD
Number of subjects: 184

Group type: COMPARATOR
Intervention: Depressed Veterans without PTSD
Number of subjects: 184
Study: 34156716

Group type: EXPERIMENTAL
Intervention: Clinical examination focusing on auxology and genital development
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Blood (serum, plasma, DNA) and urine samples collected at each visit
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Parental questionnaires and clinical examinations
Number of subjects: 268
Study: 34156874

Group type: EXPERIMENTAL
Intervention: huCART19 (humanized CD19 CAR T-cell product)
Number of subjects: 74
Study: 34157072

Group type: EXPERIMENTAL
Intervention: Urothelial component of MIBC tumors with secondary variant histology
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Micropapillary cases
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sarcomatoid tumors
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Small cell cases
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Squamous variant cases
Number of subjects: 173
Study: 34157616

Group type: EXPERIMENTAL
Intervention: Regorafenib (60-93 mg/m2) administered orally once daily for 3 weeks on/1 week off; recommended phase 2 dose is 82 mg/m2.
Number of subjects: 41
Study: 34157782

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (125 mg daily; 21 days on and 7 days off)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (Duffy null variant)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (wild-type variant)
Number of subjects: 35
Study: 34157896

Group type: EXPERIMENTAL
Intervention: Mild impact exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34157997

Group type: EXPERIMENTAL
Intervention: Radial ultrasound (r-US)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meander-like ultrasound (m-US)
Number of subjects: 0
Study: 34158028

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 936

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 936
Study: 34158082

Group type: EXPERIMENTAL
Intervention: Traditional gender beliefs
Number of subjects: 2792

Group type: COMPARATOR
Intervention: Progressive gender beliefs
Number of subjects: 2792
Study: 34158124

Group type: EXPERIMENTAL
Intervention: Autologous PRP injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Steroid/anesthetic injection (standard care)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injection with normal saline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 34158129

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss plus Weight-Related VR app
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard Behavioral Weight Loss plus Non-Weight-Related VR app
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall VR program
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VR footage
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adverse effects of VR
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Preference for VR approach
Number of subjects: 15
Study: 34158456

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) with Acute Exacerbation (AE)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) without Acute Exacerbation (AE)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) with AE
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) without AE
Number of subjects: 559
Study: 34158835

Group type: EXPERIMENTAL
Intervention: Biologicals exposed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory exposed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exposed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 0
Study: 34159342

Group type: EXPERIMENTAL
Intervention: 800 mg molnupiravir
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 400 mg molnupiravir
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 34159343

Group type: EXPERIMENTAL
Intervention: Subcutaneous REGEN-COV 1200mg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 34159344

Group type: EXPERIMENTAL
Intervention: Subcutaneous REGEN-COV (1200 mg)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study: 34159355

Group type: EXPERIMENTAL
Intervention: Plasma choline
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Plasma betaine
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Choline and betaine combined
Number of subjects: 646

Group type: COMPARATOR
Intervention: Control group (free of recurrent cardiovascular events)
Number of subjects: 646
Study: 34159373

Group type: EXPERIMENTAL
Intervention: Fasting plasma FGF21 concentration
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 109
Study: 34159555

Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PALP/IOUS/CEIOUS
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IOUS/CEIOUS
Number of subjects: 47

Group type: COMPARATOR
Intervention: Preoperative imaging
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CEIOUS
Number of subjects: 47
Study: 34159577

Group type: EXPERIMENTAL
Intervention: Single intravenous anti-pseudomonal antibiotic therapy
Number of subjects: 356

Group type: COMPARATOR
Intervention: Combination intravenous anti-pseudomonal antibiotic therapy
Number of subjects: 356
Study: 34160085

Group type: EXPERIMENTAL
Intervention: Adjustments to the HPC collection process and procedure
Number of subjects: 2
Study: 34160290

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: V3-loop genotype analysis
Number of subjects: 16
Study: 34160684

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with modified FOLFOX6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified FOLFOX6 (reduced dose due to safety concerns)
Number of subjects: 0
Study: 34160752

Group type: EXPERIMENTAL
Intervention: Talazoparib 0.75 mg once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Talazoparib 1.0 mg once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Talazoparib (both doses)
Number of subjects: 9
Study: 34160791

Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG) with interactive lifestyle educational software and connected devices
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (CG) with routine follow-up
Number of subjects: 282
Study: 34161579

Group type: EXPERIMENTAL
Intervention: Mosquito bite-induced Plasmodium vivax controlled human malaria infection (PvCHMI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quantitative PCR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quantitative real-time reverse-transcription PCR
Number of subjects: 100
Study: 34161597

Group type: EXPERIMENTAL
Intervention: Request for organ donation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Conversations with ICU physicians
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Presence of a documented will
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Opt-out policy for organ donation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Objection law for organ donation
Number of subjects: 167
Study: 34161631

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34161649

Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Number of subjects: 10
Study: 34161665

Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Berotralstat 110 mg once daily
Number of subjects: 227
Study: 34161704

Group type: EXPERIMENTAL
Intervention: Adagrasib
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 38
Study: 34162178

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 186
Study: 34162181

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Aspirin plus anticoagulant
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Periods of thrombocytosis (>600×10^9/L)
Number of subjects: 2510
Study: 34162264

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Other CDI therapies
Number of subjects: 294
Study: 34162404

Group type: EXPERIMENTAL
Intervention: Standard intensive chemotherapy
Number of subjects: 563
Study: 34162435

Group type: EXPERIMENTAL
Intervention: CAP-RA questionnaire
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Weekly pain and fatigue data collection via text messages
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing modalities
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Blood markers, swollen joints, and ultrasound scans
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of CAP-RA questionnaire
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CAP-RA psychometric properties and predictive validity
Number of subjects: 250
Study: 34162668

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34162982

Group type: EXPERIMENTAL
Intervention: Prenatal MMC repair (fetoscopic or open-hysterotomy)
Number of subjects: 63
Study: 34163157

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: All doses of Mepolizumab (100 mg and 300 mg SC)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study: 34163180

Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg intravenously or 100 mg subcutaneously)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 34164554

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34164709

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) with corticosteroid treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) with occurrence of irAE
Number of subjects: 123
Study: 34164713

Group type: EXPERIMENTAL
Intervention: Tivantinib (120-360 mg orally twice daily) + Bevacizumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tivantinib + Bevacizumab
Number of subjects: 11
Study: 34164711

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 5 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 5 mM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 5 mM
Number of subjects: 0
Study: 34164803

Group type: EXPERIMENTAL
Intervention: Reduced dietary salt intake (mean -73.51 mmol/day, equivalent to 4.2 g or 1690 mg sodium/day)
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Reduced dietary salt intake
Number of subjects: 1197
Study: 34164952

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 375 mg/m² intravenous infusions during the initial 6-month remission-induction phase.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 375 mg/m² intravenous infusions.
Number of subjects: 25
Study: 34165180

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients
Number of subjects: 2848

Group type: COMPARATOR
Intervention: Spontaneous coronary artery dissection (SCAD) patients
Number of subjects: 2848
Study: 34165201

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (b.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34165661

Group type: EXPERIMENTAL
Intervention: Rapid-flow expulsion maneuver (RFEM)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 241
Study: 34165694

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; 5 days at baseline; 3 days at 12 months)
Number of subjects: 511
Study: 34166063

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0
Study: 34166150

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 83182

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 83182
Study: 34166393

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (Pyramax)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Methylene blue
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pyronaridine
Number of subjects: 4
Study: 34166508

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: All REQUEST patients
Number of subjects: 1016
Study: 34166588

Group type: EXPERIMENTAL
Intervention: Combined Mood Stabilizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34166589

Group type: EXPERIMENTAL
Intervention: Adjunctive Mood Stabilizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0